According to the microelectrophysiological research notes, the pressure pulse ablation catheter project independently developed by the company has entered the follow-up phase. The core products of the participating company Shanghai Shangyang Medical Technology Co., Ltd., are disposable magnetoelectric double positioning pulsed electric field ablation catheters and cardiac pulse electric field ablation devices currently in the final stage of clinical follow-up. It is expected that they will obtain a registration certificate from the State Drug Administration in the first half of 2025.
微电生理：参股公司核心产品预计2025年可获注册证书
Microelectrophysiology: Participating companies' core products are expected to obtain registration certificates in 2025
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.